Pharmather reports positive tolerability and dose-finding results in its clinical trial of a ketamine-based drug for Parkinson's disease as it prepares for a Phase III trial.
Pharmather reports positive tolerability and dose-finding results in its clinical trial of a ketamine-based drug for Parkinson's disease as it prepares for a Phase III trial.
For 50 years Western governments have relentlessly undermined the mental health of their citizens while also criminalizing the only effective drugs for treating mental health.
Revitalist Lifestyle and Wellness announces a new initiative focusing on providing access to mental health therapies for veterans and first-responders.
Wesana Health reports positive treatment results in combining traditional antidepressants with psilocybin-based therapy.
Awakn Life Sciences announces closing a a CAD $3.25 million private placement, with units priced at $1.60 along with a half-warrant with an exercise price of $2.20.
Red Light Holland announces the first-ever import of psilocybin mushrooms into St. Vincent and the Grenadines.
Awaken receives regulatory approval to begin ketamine-based therapies in its flagship London mental health clinic.
Ketamine Wellness Centers, a subsidiary of Delic Holdings, announces the grand opening of its 13th ketamine clinic.
Novamind announces it will most MindMed's Phase IIb clinical trial of LSD-based therapy for generalized anxiety disorder (GAD).
MINDCURE announces the completion of its strategic review and new cost saving measures.
Psychedelics Have Proven Potential To Disrupt Entire Mental Healthcare Industry
Get Your Guide To “Ground Floor” Opportunity In Psychedelic Stocks Now